Mizuho Raises Quest Diagnostics (NYSE:DGX) Price Target to $235.00

Quest Diagnostics (NYSE:DGX) had its price target boosted by investment analysts at Mizuho from $210.00 to $235.00 in a research note issued on Thursday, Marketbeat Ratings reports. The firm presently has an “outperform” rating on the medical research company’s stock. Mizuho’s price objective suggests a potential upside of 13.71% from the company’s previous close.

A number of other equities analysts also recently weighed in on the stock. Morgan Stanley set a $207.00 target price on shares of Quest Diagnostics and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Piper Sandler increased their price target on Quest Diagnostics from $190.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Robert W. Baird set a $219.00 price objective on Quest Diagnostics in a research note on Wednesday. Wall Street Zen lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Quest Diagnostics in a report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and an average price target of $208.93.

Quest Diagnostics Price Performance

Shares of DGX opened at $206.66 on Thursday. The business has a 50-day moving average of $183.25 and a 200-day moving average of $182.40. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market capitalization of $22.99 billion, a price-to-earnings ratio of 23.62, a price-to-earnings-growth ratio of 2.67 and a beta of 0.66. Quest Diagnostics has a 1 year low of $157.20 and a 1 year high of $213.20.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, February 10th. The medical research company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.35 by $0.07. Quest Diagnostics had a return on equity of 15.57% and a net margin of 8.99%.The business had revenue of $2.81 billion for the quarter, compared to analysts’ expectations of $2.75 billion. During the same period in the prior year, the business posted $2.23 earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. As a group, equities research analysts anticipate that Quest Diagnostics will post 9.7 earnings per share for the current year.

Quest Diagnostics declared that its Board of Directors has initiated a stock repurchase program on Tuesday, February 10th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 4.7% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Insider Transactions at Quest Diagnostics

In other news, Director Vicky B. Gregg sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $191.76, for a total transaction of $239,700.00. Following the completion of the sale, the director owned 17,037 shares in the company, valued at $3,267,015.12. The trade was a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Patrick Plewman sold 5,662 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $204.00, for a total value of $1,155,048.00. Following the completion of the transaction, the senior vice president owned 15,381 shares in the company, valued at approximately $3,137,724. This represents a 26.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 69,951 shares of company stock worth $13,473,408. 8.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Quest Diagnostics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quattro Advisors LLC bought a new position in Quest Diagnostics in the 4th quarter valued at about $25,000. JFS Wealth Advisors LLC lifted its holdings in shares of Quest Diagnostics by 114.3% in the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 80 shares in the last quarter. Harbor Investment Advisory LLC lifted its holdings in shares of Quest Diagnostics by 113.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 83 shares in the last quarter. MTM Investment Management LLC purchased a new position in shares of Quest Diagnostics during the second quarter valued at approximately $29,000. Finally, Sittner & Nelson LLC bought a new stake in Quest Diagnostics during the fourth quarter worth $29,000. 88.06% of the stock is owned by institutional investors.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Better-than-expected Q4 results and 2026 guidance: Q4 EPS $2.42 vs. $2.35 est., revenue $2.81B vs. $2.75B est., and FY‑2026 EPS guidance of $9.45–$9.65 — supports the recent run to a 12‑month high. Quest Diagnostics Hits New 12-Month High on Better-Than-Expected Earnings
• Positive Sentiment: $1.0 billion share repurchase authorization (~4.7% of shares outstanding): board buyback typically supports EPS and signals management thinks shares are undervalued. Quest Diagnostics Board Approves Stock Repurchase Program
• Positive Sentiment: Dividend increase: quarterly dividend raised to $0.86 (annualized $3.44), up from $0.80 — incremental income support and a sign of confidence in cash flow. Quest Diagnostics Has Announced That It Will Be Increasing Its Dividend To $0.86
• Positive Sentiment: Analyst bullishness: Mizuho upgraded to Buy and raised its target to $235 (largest recent target raise), and Citigroup published a constructive price‑appreciation forecast — these lifts can attract demand and support the stock. Quest Diagnostics Gets a Buy from Mizuho Securities Citigroup Forecasts Strong Price Appreciation for Quest Diagnostics
• Neutral Sentiment: Valuation/mean‑reversion questions: coverage pieces note DGX is at a 52‑week high and review whether recent strength is sustainable — useful for gauging risk/reward but not new fundamental data. Can the Run Continue?
• Negative Sentiment: Insider selling: SVP Patrick Plewman sold 5,662 shares (~27% of his holding) at about $204 — insider sales can be viewed negatively by some investors even when proceeds are routine. SVP Patrick Plewman Sells 5,662 Shares

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.